Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has completed its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient (API) supporting its lead oncology candidate, ONC010. The milestone, achieved in collaboration with Dalton Pharma Services, establishes a qualified reference standard to support analytical testing, manufacturing consistency, quality control, and future regulatory and clinical activities.
The completion of the reference standard program strengthens the company's chemistry, manufacturing and controls (CMC) framework. It follows recent progress in API manufacturing, precursor scale-up, analytical method development, and chiral purity testing. Onco-Innovations stated that the program supports its broader strategy of advancing ONC010 toward clinical readiness, while ongoing analytical development efforts continue across stability testing, impurity profiling, formulation characterization, and quality control systems.
The news is significant for investors and stakeholders as it demonstrates Onco-Innovations' commitment to rigorous drug development standards. A robust CMC package is essential for regulatory submissions, including Investigational New Drug (IND) applications, and ultimately for clinical trials. By establishing a qualified reference standard, the company ensures that its API can be consistently manufactured and tested, reducing risks associated with batch-to-batch variability.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumours. For more information about Onco-Innovations, visit the company's newsroom at https://ibn.fm/ONNVF.
The full press release regarding the reference standard program is available at https://ibn.fm/EefIN. This development positions Onco-Innovations to move forward with its ONC010 program, which targets solid tumours and could address significant unmet medical needs in oncology.
